Dimensional Fund Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-27,121
| Closed | -$45.8K | – | 3284 |
|
|
2025
Q3 | $45.8K | Sell |
27,121
-13,328
| -33% | -$15.8K | ﹤0.01% | 3245 |
|
|
2025
Q2 | $36.7K | Hold |
40,449
| – | – | ﹤0.01% | 3251 |
|
|
2025
Q1 | $18.3K | Hold |
40,449
| – | – | ﹤0.01% | 3308 |
|
|
2024
Q4 | $20.3K | Hold |
40,449
| – | – | ﹤0.01% | 3326 |
|
|
2024
Q3 | $36.6K | Hold |
40,449
| – | – | ﹤0.01% | 3316 |
|
|
2024
Q2 | $40.3K | Hold |
40,449
| – | – | ﹤0.01% | 3328 |
|
|
2024
Q1 | $59.9K | Hold |
40,449
| – | – | ﹤0.01% | 3321 |
|
|
2023
Q4 | $44.1K | Hold |
40,449
| – | – | ﹤0.01% | 3358 |
|
|
2023
Q3 | $47.7K | Hold |
40,449
| – | – | ﹤0.01% | 3384 |
|
|
2023
Q2 | $57K | Hold |
40,449
| – | – | ﹤0.01% | 3394 |
|
|
2023
Q1 | $60.7K | Sell |
40,449
-8,015
| -17% | -$11.2K | ﹤0.01% | 3368 |
|
|
2022
Q4 | $56 | Hold |
48,464
| – | – | ﹤0.01% | 3386 |
|
|
2022
Q3 | $55K | Sell |
48,464
-16,691
| -26% | -$24.5K | ﹤0.01% | 3395 |
|
|
2022
Q2 | $103K | Sell |
65,155
-63,528
| -49% | -$83.8K | ﹤0.01% | 3329 |
|
|
2022
Q1 | $198K | Hold |
128,683
| – | – | ﹤0.01% | 3313 |
|
|
2021
Q4 | $315K | Hold |
128,683
| – | – | ﹤0.01% | 3266 |
|
|
2021
Q3 | $324K | Hold |
128,683
| – | – | ﹤0.01% | 3264 |
|
|
2021
Q2 | $367K | Hold |
128,683
| – | – | ﹤0.01% | 3223 |
|
|
2021
Q1 | $302K | Buy |
128,683
+4,323
| +3% | +$10.4K | ﹤0.01% | 3227 |
|
|
2020
Q4 | $219K | Hold |
124,360
| – | – | ﹤0.01% | 3208 |
|
|
2020
Q3 | $116K | Sell |
124,360
-21,728
| -15% | -$19.2K | ﹤0.01% | 3255 |
|
|
2020
Q2 | $127K | Sell |
146,088
-5,399
| -4% | -$4.75K | ﹤0.01% | 3252 |
|
|
2020
Q1 | $125K | Hold |
151,487
| – | – | ﹤0.01% | 3255 |
|
|
2019
Q4 | $135K | Sell |
151,487
-3,363
| -2% | -$2.8K | ﹤0.01% | 3290 |
|
|
2019
Q3 | $152K | Hold |
154,850
| – | – | ﹤0.01% | 3304 |
|
|
2019
Q2 | $170K | Hold |
154,850
| – | – | ﹤0.01% | 3340 |
|
|
2019
Q1 | $203K | Sell |
154,850
-1,871
| -1% | -$2.33K | ﹤0.01% | 3308 |
|
|
2018
Q4 | $143K | Sell |
156,721
-22,411
| -13% | -$34.3K | ﹤0.01% | 3319 |
|
|
2018
Q3 | $368K | Hold |
179,132
| – | – | ﹤0.01% | 3221 |
|
|
2018
Q2 | $323K | Hold |
179,132
| – | – | ﹤0.01% | 3188 |
|
|
2018
Q1 | $422K | Hold |
179,132
| – | – | ﹤0.01% | 3132 |
|
|
2017
Q4 | $337K | Hold |
179,132
| – | – | ﹤0.01% | 3153 |
|
|
2017
Q3 | $445K | Buy |
179,132
+41,114
| +30% | +$102K | ﹤0.01% | 3120 |
|
|
2017
Q2 | $380K | Buy |
+138,018
| New | +$386K | ﹤0.01% | 3130 |
|
Other funds holding LCTX
BC
DC
RA
Dimensional Fund Advisors's LCTX Position: Q4 2025 in Review
Dimensional Fund Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 27,121 shares — an estimated $45.8K sold.
Dimensional Fund Advisors first reported a position in LCTX in Q2 2017 and held it in 34 quarters. The position peaked at $445K in Q3 2017. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.
- Dimensional Fund Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
- Dimensional Fund Advisors sold 27,121 Lineage Cell Therapeutics shares in Q4 2025, an estimated $45.8K.
- Dimensional Fund Advisors first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 34 quarters.
- Dimensional Fund Advisors's Lineage Cell Therapeutics position peaked at $445K in Q3 2017.
- 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.
Based on Dimensional Fund Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.